Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Trial Profile

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 26 Feb 2015 Planned End Date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 26 Feb 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top